BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 37885161)

  • 21. Sulforaphane synergistically enhances the cytotoxicity of arsenic trioxide in multiple myeloma cells via stress-mediated pathways.
    Doudican NA; Wen SY; Mazumder A; Orlow SJ
    Oncol Rep; 2012 Nov; 28(5):1851-8. PubMed ID: 22922937
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Arsenic trioxide-enhanced, matrine-induced apoptosis in multiple myeloma cell lines.
    Yu Q; Chen B; Zhang X; Qian W; Ye B; Zhou Y
    Planta Med; 2013 Jun; 79(9):775-81. PubMed ID: 23700110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effects of PSMB5 on proliferation and bortezomib chemo-resistance in human myeloma cells and its related molecular mechanisms].
    Mo HM; Wu QY; Han DY; Liu R; Ma X; Zhou P; Xu KL
    Zhonghua Xue Ye Xue Za Zhi; 2017 Dec; 38(12):1053-1057. PubMed ID: 29365400
    [No Abstract]   [Full Text] [Related]  

  • 24. Synergistic Apoptotic Effects of Bortezomib and Methylstat on Multiple Myeloma Cells.
    Kacı FN; Kiraz Y; Çekdemir D; Baran Y
    Arch Med Res; 2020 Apr; 51(3):187-193. PubMed ID: 32111493
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Network-Based Analysis of Bortezomib Pharmacodynamic Heterogeneity in Multiple Myeloma Cells.
    Ramakrishnan V; Mager DE
    J Pharmacol Exp Ther; 2018 Jun; 365(3):734-751. PubMed ID: 29632237
    [TBL] [Abstract][Full Text] [Related]  

  • 26. TM-233, a novel analog of 1'-acetoxychavicol acetate, induces cell death in myeloma cells by inhibiting both JAK/STAT and proteasome activities.
    Sagawa M; Tabayashi T; Kimura Y; Tomikawa T; Nemoto-Anan T; Watanabe R; Tokuhira M; Ri M; Hashimoto Y; Iida S; Kizaki M
    Cancer Sci; 2015 Apr; 106(4):438-46. PubMed ID: 25613668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MLN4924, an NAE inhibitor, suppresses AKT and mTOR signaling via upregulation of REDD1 in human myeloma cells.
    Gu Y; Kaufman JL; Bernal L; Torre C; Matulis SM; Harvey RD; Chen J; Sun SY; Boise LH; Lonial S
    Blood; 2014 May; 123(21):3269-76. PubMed ID: 24713927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inactivation of CK1α in multiple myeloma empowers drug cytotoxicity by affecting AKT and β-catenin survival signaling pathways.
    Manni S; Carrino M; Manzoni M; Gianesin K; Nunes SC; Costacurta M; Tubi LQ; Macaccaro P; Taiana E; Cabrelle A; Barilà G; Martines A; Zambello R; Bonaldi L; Trentin L; Neri A; Semenzato G; Piazza F
    Oncotarget; 2017 Feb; 8(9):14604-14619. PubMed ID: 28099937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The immunomodulator AS101 induces growth arrest and apoptosis in multiple myeloma: association with the Akt/survivin pathway.
    Hayun M; Naor Y; Weil M; Albeck M; Peled A; Don J; Haran-Ghera N; Sredni B
    Biochem Pharmacol; 2006 Nov; 72(11):1423-31. PubMed ID: 16889755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma.
    Cirstea D; Hideshima T; Rodig S; Santo L; Pozzi S; Vallet S; Ikeda H; Perrone G; Gorgun G; Patel K; Desai N; Sportelli P; Kapoor S; Vali S; Mukherjee S; Munshi NC; Anderson KC; Raje N
    Mol Cancer Ther; 2010 Apr; 9(4):963-75. PubMed ID: 20371718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells.
    Bai LY; Omar HA; Chiu CF; Chi ZP; Hu JL; Weng JR
    Cancer Chemother Pharmacol; 2011 Aug; 68(2):489-96. PubMed ID: 21072520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Knockdown of DEPTOR induces apoptosis, increases chemosensitivity to doxorubicin and suppresses autophagy in RPMI-8226 human multiple myeloma cells in vitro.
    Zhang H; Chen J; Zeng Z; Que W; Zhou L
    Int J Mol Med; 2013 May; 31(5):1127-34. PubMed ID: 23503641
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pure antiestrogen-induced G1-arrest in myeloma cells results from the reduced kinase activity of cyclin D3/CDK6 complexes whereas apoptosis is mediated by endoplasmic reticulum-dependent caspases.
    Gauduchon J; Seguin A; Marsaud V; Clay D; Renoir JM; Sola B
    Int J Cancer; 2008 May; 122(9):2130-41. PubMed ID: 18183592
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Heme oxygenase-1 inhibition mediates Gas6 to enhance bortezomib-sensitivity in multiple myeloma via ERK/STAT3 axis.
    Zhang Z; Wang W; Ma D; Xiong J; Kuang X; Zhang S; Fang Q; Wang J
    Aging (Albany NY); 2020 Apr; 12(8):6611-6629. PubMed ID: 32298237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BNIP3 overexpression may promote myeloma cell apoptosis by enhancing sensitivity to bortezomib via the p38 MAPK pathway.
    Xiao P; Chen X; Dong Z; Fan W; Chen Y; Su J; Wang Q; Ma L
    Hematology; 2023 Dec; 28(1):2231739. PubMed ID: 37401850
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bioinformatics Analysis Reveals FOXM1/BUB1B Signaling Pathway as a Key Target of Neosetophomone B in Human Leukemic Cells: A Gene Network-Based Microarray Analysis.
    Kuttikrishnan S; Masoodi T; Sher G; Bhat AA; Patil K; El-Elimat T; Oberlies NH; Pearce CJ; Haris M; Ahmad A; Alali FQ; Uddin S
    Front Oncol; 2022; 12():929996. PubMed ID: 35847923
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacogenomics and chemical library screens reveal a novel SCF
    Malek E; Abdel-Malek MA; Jagannathan S; Vad N; Karns R; Jegga AG; Broyl A; van Duin M; Sonneveld P; Cottini F; Anderson KC; Driscoll JJ
    Leukemia; 2017 Mar; 31(3):645-653. PubMed ID: 27677741
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells.
    Baumann P; Mandl-Weber S; Völkl A; Adam C; Bumeder I; Oduncu F; Schmidmaier R
    Mol Cancer Ther; 2009 Feb; 8(2):366-75. PubMed ID: 19174558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The oral protein-kinase C beta inhibitor enzastaurin (LY317615) suppresses signalling through the AKT pathway, inhibits proliferation and induces apoptosis in multiple myeloma cell lines.
    Neri A; Marmiroli S; Tassone P; Lombardi L; Nobili L; Verdelli D; Civallero M; Cosenza M; Bertacchini J; Federico M; De Pol A; Deliliers GL; Sacchi S
    Leuk Lymphoma; 2008 Jul; 49(7):1374-83. PubMed ID: 18452078
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HDAC6-Selective Inhibitor Overcomes Bortezomib Resistance in Multiple Myeloma.
    Lee SW; Yeon SK; Kim GW; Lee DH; Jeon YH; Yoo J; Kim SY; Kwon SH
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33572814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.